EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti–Cancer Treatment

Karin Purshouse iD, John P Thomson, Mahéva Vallet, Lorna Alexander, Isaac Bonisteel, Maree Brennan, David A Cameron, Jonine D Figueroa, Elizabeth Furrie, Pamela Haig, Mattea Heck, Hugh McCaughan und 7 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyac257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Karin Purshouse und 18 weiteren Autor:innen. Beteiligte Einrichtung: Edinburgh Cancer Centre, NHS Lothian, Crewe Road South, Edinburgh, UK. Hauptthemen laut MEDLINE: COVID-19, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHS Lothian Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer and anti-cancer treatment (ACT) may be risk factors for severe SARS-CoV-2 infection and limited vaccine efficacy. Long–term longitudinal studies are needed to evaluate these risks. The Scottish COVID cancer immunity prevalence (SCCAMP) study characterizes the incidence and outcomes of SARS-CoV-2 infection and vaccination in patients with solid tumors undergoing ACT. This preliminary analysis includes 766 patients recruited since May 2020.

Methods

Patients with solid-organ cancers attending secondary care for active ACT consented to the collection of routine electronic health record data and serial blood samples over 12 months. Blood samples were tested for total SARS-CoV-2 antibody.

Results

A total of 766 participants were recruited between May 28, 2020 and October 31, 2021. Most received cytotoxic chemotherapy (79%). Among the participants, 48 (6.3%) were tested positive for SARS-CoV-2 by PCR. Infection rates were unaffected by ACT, largely aligning with the local population. Mortality proportion was not higher with a recent positive SARS-CoV-2 PCR (10.4% vs 10.6%). Multivariate analysis revealed lower infection rates in vaccinated patients regardless of chemotherapy (HR 0.307 [95% CI, 0.144-0.6548]) or immunotherapy (HR 0.314 [95% CI, 0.041-2.367]) treatment. A total of 96.3% of patients successfully raised SARS-CoV-2 antibodies after >2 vaccines. This was independent of the treatment type.

Conclusion

This is the largest on-going longitudinal real-world dataset of patients undergoing ACT during the early stages of the COVID-19 pandemic. This preliminary analysis demonstrates that patients with solid tumors undergoing ACT have high protection from SARS-CoV-2 infection following COVID-19 vaccination. The SCCAMP study will evaluate long–term COVID-19 antibody trends, focusing on specific ACTs and patient subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NeoplasmsHumansSARS-CoV-2COVID-19 VaccinesCross-Sectional StudiesLongitudinal StudiesPandemicsImmunityScotlandVaccination

Stichwörter der Autor:innen

COVID-19SARS-CoV-2SCCAMPanti-cancer treatmentchemotherapy

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Edinburgh Cancer Centre, NHS Lothian, Crewe Road South, Edinburgh, UK.
  • Institute of Genetics and Cancer, The University of Edinburgh, Western General Hospital, Edinburgh, UK.
  • The University of Edinburgh Medical School, The University of Edinburgh, Chancellor's Building, Edinburgh BioQuarter, Edinburgh, UK.
  • Usher Institute, Centre for Population Health Sciences, Old Medical School, Teviot Place, Edinburgh, UK.
  • Department of Immunology, Ninewells Hospital and Dundee Medical School, Dundee, UK.
  • Clinical Infection Research Group, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK.

ORCID-Profile: Karin Purshouse, Peter S Hall

Förderung

  • NHS Lothian Charity

Zitieren

APA

Purshouse, K., Thomson, J. P., Vallet, M., Alexander, L., Bonisteel, I., Brennan, M., Cameron, D. A., Figueroa, J. D., Furrie, E., Haig, P., Heck, M., McCaughan, H., Mitchell, P., McVicars, H., Primrose, L., Silva, I., Templeton, K., Wilson, N., & Hall, P. S. (2023). The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti–Cancer Treatment. The Oncologist. https://doi.org/10.1093/oncolo/oyac257

Vancouver

Purshouse K, Thomson JP, Vallet M, Alexander L, Bonisteel I, Brennan M, et al. The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti–Cancer Treatment. The Oncologist. 2023. doi:10.1093/oncolo/oyac257

BibTeX
@article{Purshouse2023,
  author = {Purshouse, Karin and Thomson, John P and Vallet, Mahéva and Alexander, Lorna and Bonisteel, Isaac and Brennan, Maree and Cameron, David A and Figueroa, Jonine D and Furrie, Elizabeth and Haig, Pamela and Heck, Mattea and McCaughan, Hugh and Mitchell, Paul and McVicars, Heather and Primrose, Lorraine and Silva, Ines and Templeton, Kate and Wilson, Natalie and Hall, Peter S},
  title = {The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti–Cancer Treatment},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyac257}
}
Kostenlos starten →